OPK Earnings

OPK reported its FY2025Q4 earnings on 2026-02-25, showcasing a revenue of 0.00 against an estimate of 158.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.07 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following OPK's FY2025Q4 earnings announcement on 2026-02-25, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, OPK's stock price tends to shift by an average of +2.92% in the 10 days leading up to earnings and +3.65% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate OPK’s annual revenue to reach 140.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -6.72% and EPS estimates Revise Downward by -14.86% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between OPK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -6.72%, while EPS estimates moved Revise Downward by -14.86% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, OPK's stock price typically moves by +2.92% in the 10 days before its earnings and +3.65% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 140.00M.

The earnings call presents a mixed picture. Financial performance shows some decline in net income, but there's optimism in product development with potential growth in the 4Kscore product and new collaborations. Market strategy is unclear, with slow market conversion for Pfizer products. Expenses are high, impacting financial health. The shareholder return plan is not explicitly positive or negative. The Q&A reveals uncertainties in efficacy and market conversion. Overall, the rating is neutral due to balanced positives and negatives, with no strong catalysts for significant stock price movement.